This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Richard A. Kronmal, PhD

JAMA. 1985;253(14):2091-2093.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

THE LIPID Research Clinics Coronary Primary Prevention Trial (LRC-CPPT) was a randomized double-blind clinical trial testing the efficacy of the cholesterollowering drug cholestyramine taken in conjunction with a cholesterol-lowering diet in reducing the risk of coronary heart disease (CHD) in asymptomatic middle-aged men with primary hypercholesterolemia. The CPPT trial results were described in detail in two recent articles in THE JOURNAL.^1,2 The first article presented the results of the clinical trial itself, comparing the occurrence of cardiovascular disease in the two study groups: (1) cholestyramine plus diet and (2) placebo plus diet. The second article analyzed data from the two groups separately and within each group examined the relationship of lowering of levels of total cholesterol and of low-density lipoprotein-cholesterol (LDL-C) to the incidence of primary cardiovascular end points. The trial was well designed and superbly carried out. However, the reported conclusions seem to go beyond what is reasonably . . . [Full Text PDF of this Article]

Author Affiliations
From the Department of Biostatistics, University of Washington, Seattle.

Footnotes
Reprint requests to Department of Biostatistics, SC 32, University of Washington School of Public Health and Community Medicine, Seattle, WA 98195 (Dr Kronmal).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?